A recent retrospective analysis used immunohistochemistry (IHC) assays to estimate the fraction of PD-1hiCD8+ T cells in the tumor microenvironment (TME) and demonstrated that this was positively associated with treatment response and patient survival in cases of NSCLC treated with PD-1 blockade (13). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.